melanoma
Oncology · 2011–2023
46decisions
15medicines
27carried consumer input
810individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| relatlimab and nivolumab Treatment of patients with unresectable Stage III or IV malignant melanoma who are PD-1 inhibitor-naive. | Jul 2023 | Recommended with restriction | input received Rare Cancers Australia |
| relatlimab with nivolumab Treatment of patients with unresectable Stage III or IV malignant melanoma who have not previously received systemic anti-cancer therapy for this indication. | Jul 2022 | Not recommended | 6 individuals Skin Cancer Advocacy Network · Melanoma Patients Australia · Medical Oncology Group |
| nivolumab + ipilimumab Treatment of unresectable Stage III or IV malignant melanoma in patients who experience melanoma recurrence while receiving or within 6 months of completing… | Nov 2022 | Recommended with restriction | 1 individuals |
| pembrolizumab Addition of 400 mg every six weeks flat dosing regimen for the treatment of unresectable Stage III or Stage IV malignant melanoma, and first-line treatment of… | Mar 2020 | Recommended | 2 individuals |
| pembrolizumab First-line treatment of unresectable Stage III or Stage IV malignant melanoma in patients with a BRAF V600 mutation who have not received prior systemic… | Mar 2020 | Recommended with restriction | input received Medical Oncology Group |
| pembrolizumab Adjuvant treatment of resected Stage IIIB, IIIC or IIID malignant melanoma. | Mar 2020 | Recommended | input received Medical Oncology Group |
| dabrafenib and trametinib Adjuvant treatment of patients with BRAF V600 mutation positive resected Stage IIIB, IIIC or IIID melanoma following complete surgical resection. | Jul 2019 | Recommended with restriction | 3 individuals |
| nivolumab Adjuvant treatment of patients with completely resected Stage IIIB, IIIC, IIID and Stage IV melanoma (staged using the 8th edition of the AJCC melanoma staging… | Jul 2019 | Deferred | 18 individuals |
| pembrolizumab Adjuvant treatment of patients with completely resected Stage III malignant melanoma (Stage IIIB, IIIC or IIID) at high risk of recurrent disease. | Jul 2019 | Not recommended | 2 individuals |
| dabrafenib + trametinib Adjuvant treatment for patients with BRAF V600 mutation positive, completely resected Stage III melanoma. | Mar 2019 | Deferred | input received |
| nivolumab Adjuvant treatment for completely resected Stage III or IV melanoma (excluding Stage IIIA and uveal melanoma). | Mar 2019 | Not recommended | 67 individuals |
| nivolumab Addition of two flat dosing regimens (240 mg Q2W and 480 mg Q4W) to existing weight-based dosing (3 mg/kg Q2W) for multiple PBS-listed indications including… | Mar 2019 | Recommended | unclear |
| nivolumab First-line treatment of unresectable Stage III or Stage IV malignant melanoma with a BRAF V600 mutation, as monotherapy or in combination with ipilimumab. | Nov 2019 | Recommended | 21 individuals |
| nivolumab Adjuvant treatment of completely resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma. | Nov 2019 | Recommended with restriction | none received |
| pembrolizumab Adjuvant treatment of patients with completely resected Stage IIIB, IIIC, and IIID melanoma. | Nov 2019 | Deferred | 3 individuals |
| nivolumab and ipilimumab Treatment of unresectable Stage III or Stage IV malignant melanoma. In patients with BRAF V600 mutation negative melanoma, unrestricted by treatment line; in… | Jul 2018 | Recommended with restriction | 310 individuals |
| nivolumab Adjuvant treatment for completely resected Stage III or Stage IV melanoma. | Jul 2018 | Recommended with restriction | 40 individuals |
| pembrolizumab Treatment of unresectable Stage III or Stage IV malignant melanoma. The submission requested a change in dosing regimen from weight-based (2 mg/kg) to fixed… | Mar 2018 | Recommended | unclear |
| encorafenib; binimetinib Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. The combination is indicated for adult patients with unresectable Stage III or… | Nov 2018 | Recommended with restriction | 6 individuals |
| pembrolizumab Adjuvant treatment for completely resected Stage III malignant melanoma. | Nov 2018 | Not recommended | 19 individuals |
| pembrolizumab Unresectable Stage III or Stage IV malignant melanoma. This submission involved removal of the weight-based dosing option to align with TGA product information… | Nov 2018 | Recommended with restriction | no section in document |
| nivolumab + ipilimumab Treatment of unresectable Stage III or Stage IV malignant melanoma. | Mar 2017 | Not recommended | 1 individuals |
| ipilimumab Treatment of unresectable stage III or stage IV malignant melanoma as monotherapy or as the sole PBS-subsidised therapy for this condition. | Jul 2016 | Recommended with restriction | input received |
| talimogene laherparepvec Treatment of unresectable stage III or stage IV malignant melanoma without visceral metastases (stage IIIb/c and stage IVM1a). | Jul 2016 | Not recommended | input received |
| trametinib Treatment of unresectable or metastatic melanoma in patients with BRAF V600 mutation, in combination with dabrafenib or as monotherapy in patients with… | Jul 2016 | Recommended with restriction | none received |
| vemurafenib + cobimetinib Treatment of BRAF V600 mutation positive unresectable or metastatic melanoma as first-line therapy. | Mar 2016 | Recommended with restriction | none received |
| pembrolizumab Treatment of unresectable Stage III or Stage IV metastatic melanoma. First-line for BRAF mutation negative patients; second-line for BRAF mutation positive… | Mar 2016 | Not recommended | none received |
| pembrolizumab Unresectable Stage III or Stage IV malignant melanoma. Treatment is restricted based on BRAF V600 mutation status and prior treatment history. | Nov 2016 | Recommended | input received |
| pembrolizumab Monotherapy treatment of unresectable or metastatic melanoma in adults. The PBS restriction places it as first-line for BRAF mutation-negative patients and… | Nov 2016 | Not recommended | input received Melanoma Patients Australia |
| ipilimumab Treatment of unresectable stage III or stage IV malignant melanoma. This item concerns the incidence and costs of treating adverse events associated with… | Jul 2015 | Noted | no section in document |
| nivolumab Treatment of unresectable Stage III or Stage IV malignant melanoma, in both BRAF wild-type and BRAF mutant patients (the latter following progression on BRAF… | Jul 2015 | Not recommended | 12 individuals |
| pembrolizumab Treatment of unresectable Stage III or Stage IV metastatic melanoma. The submission proposed PBS listing for ipilimumab-naïve patients, with separate pathways… | Mar 2015 | Recommended with restriction | 275 individuals Australian Melanoma Consumer Alliance · Melanoma Patients Australia · CanSpeak Australia |
| dabrafenib and trametinib Treatment of BRAF-mutated unresectable stage III or stage IV malignant melanoma. | Nov 2015 | Recommended with restriction | none received |
| nivolumab + ipilimumab Treatment of unresectable Stage III or Stage IV malignant melanoma (combination induction therapy followed by nivolumab monotherapy continuation phase). | Nov 2015 | Not recommended | 24 individuals |
| nivolumab Treatment of unresectable Stage III or Stage IV malignant melanoma in patients with BRAF V600 wild-type mutations who have not received prior treatment with… | Nov 2015 | Recommended | input received |
| trametinib Treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) melanoma, in combination with dabrafenib. | Mar 2014 | Not recommended | input received Medical Oncology Group |
| trametinib Treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) melanoma, in combination with dabrafenib. | Nov 2014 | Recommended with restriction | unclear |
| dabrafenib Treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma. | Jul 2013 | Recommended | no section in document |
| dabrafenib Treatment of patients with BRAF V600 mutation positive advanced (unresectable stage III) or metastatic (stage IV) melanoma. | Mar 2013 | Recommended | no section in document |
| vemurafenib Treatment of BRAF V600 mutation-positive patients with unresectable (stage IIIC) or metastatic (stage IV) melanoma with WHO performance status ≤2. | Mar 2013 | Recommended | no section in document |
| vemurafenib For the treatment of previously untreated unresectable stage IIIC or stage IV melanoma positive for the BRAF V600 mutation, or alternatively BRAF V600 mutation… | Jul 2012 | Deferred | unclear |
| vemurafenib Initial and continuing treatment of previously untreated unresectable stage IIIC or stage IV melanoma positive for BRAF V600 mutation. | Jul 2012 | Deferred | unclear |
| ipilimumab For the treatment of patients with unresectable stage III or stage IV malignant melanoma who have failed or are intolerant to prior therapy for metastatic… | Mar 2012 | Not recommended | unclear |
| ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Mar 2012 | Not recommended | unclear |
| Ipilimumab Treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | Nov 2012 | Recommended with restriction | unclear |
| ipilimumab treatment of patients with unresectable stage III or stage IV malignant melanoma who have not responded to or were intolerant to prior systemic therapy for… | 2011 | Not recommended | unclear |
Who spoke
Medical Oncology Group · Melanoma Patients Australia · Australian Melanoma Consumer Alliance · CanSpeak Australia · Rare Cancers Australia · Skin Cancer Advocacy Network
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 27 of 37 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.